Unlabelled: It is proposed to use the novel paradigm of treating cancer with hyperthermic therapy using multi-walled carbon nanotubes (MWCNT) stimulated with near infrared (NIR) irradiation.
Aim: To establish the capacity of MWCNT stimulated with NIR irradiation to destroy Erlich ascitic carcinoma (EAC) cells.
Materials And Methods: EAC cells suspension was irradiated with NIR heating lamp with a wavelength of 0.78-1.40 mm and power density of 3.5 W/cm2 over 1.5 min in the presence of MWCNT (0.1 mg/ml). The changes in the temperature of suspension with the NIR exposure time was measured using the differential cooper-constantan thermocouple. The viability of EAC cells was evaluated by trypan blue staining.
Results: The death of 95.2% of EAC cells in the presence of MWCNT was observed after 1.5 min of NIR light irradiation: thermal ablation temperature was approximately 50 degrees C.
Conclusions: It was demonstrated that addition of MWCNT to EAC cell suspension results in the photo-ablative destruction of cells exposed to short time NIR irradiation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Mathematical modeling of somatic evolution, a process impacting both host cells and microbial communities in the human body, can capture important dynamics driving carcinogenesis. Here we considered models for esophageal adenocarcinoma (EAC), a cancer that has dramatically increased in incidence over the past few decades in Western populations, with high case fatality rates due to late-stage diagnoses. Despite advancements in genomic analyses of the precursor Barrett's esophagus (BE), prevention of late-stage EAC remains a significant clinical challenge.
View Article and Find Full Text PDFProlonged neurologic symptoms following immune effector cell-associated neurotoxicity syndrome in patients with large B cell lymphoma treated with chimeric antigen receptor-modified T cell therapy.
Transplant Cell Ther
January 2025
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Background: While immune effector cell-associated neurotoxicity syndrome (ICANS) is a well-defined adverse effect associated with chimeric antigen receptor-modified T cell (CAR-T) therapy, some patients develop prolonged neurologic symptoms. Few studies have examined characteristics and outcomes of patients who develop such symptoms.
Objective: To provide an analysis of patients who developed ICANS in a single-center cohort of patients with large B-cell lymphoma (LBCL) who received commercial CAR-T and compare characteristics and outcomes between patients with vs.
CCN1 is a matricellular protein highly expressed in esophageal squamous cell carcinoma (ESCC) but hardly detectable in esophageal adenocarcinoma (EAC). Expression of CCN1 in EAC cells leads to TRAIL-mediated apoptosis. Unlike TRAIL, which primarily triggers cell death, APRIL and BAFF promote cell growth via NFκB signaling.
View Article and Find Full Text PDFReal-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett's Esophagus (BE).
Medicina (Kaunas)
December 2024
Lucid Diagnostics Inc., New York, NY 10017, USA.
Barrett's Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC). Patients with multiple risk factors for BE/EAC are recommended for screening; however, few eligible patients undergo evaluation by endoscopy. EsoGuard (EG) is a commercially available biomarker assay used to analyze esophageal cells collected non-endoscopically with EsoCheck (EC) for the qualitative detection of BE/EAC.
View Article and Find Full Text PDFIdentification of as a Potential Biomarker for Progression from Barrett's Esophagus to Esophageal Adenocarcinoma: A Comprehensive Bioinformatic Analysis.
Diagnostics (Basel)
December 2024
Dow Medical College, Dow University of Health Sciences, Karachi 74200, Pakistan.
: Barrett's esophagus (BE), with metaplastic columnar epithelium in the lower esophagus, predisposes patients to esophageal adenocarcinoma (EAC). Despite extensive research, mechanisms underlying BE progression to EAC remain unclear, and no validated biomarkers are available for clinical use. Progastricsin/Pepsinogen-C (PGC), an aspartic proteinase linked to maintaining normal epithelial morphology, is often absent in advanced gastrointestinal malignancies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!